Market Access Switzerland in a nutshell | In English

Understand the Swiss access process and gain insights for optimal patient access in Switzerland.

Understand the overall Swiss market access concept and gain key insights for optimal access to medicines in Switzerland.

Learn about the “WZW” criteria (effectiveness, appropriateness, and cost-effectiveness) applied by the Federal Office of Public Health (FOPH) to place medicines on the List of Pharmaceutical Specialities (SL).
Understand the essentials of successful value dossiers needed to engage with the Federal Medicine Commission (FMC) and the pricing reviews conducted by the FOPH.

The possibility of off-label reimbursement in accordance with Article 71a-d HIO (Health Insurance), in cooperation with health insurances, the Swissmedic approval process, and the importance of Pharmaceutical Economics and Health Technology Assessment (HTA) in Switzerland round off the program.

Focus areas:

Access process model (from admission to use)
List of pharmaceutical specialities (SL) listing from A-Z (TQV, APV, pricing models) and access via IV
Insights on the Federal Office of Public Health (FOPH/BAG) process
Creation of a successful value dossier
Off-label reimbursemendt in accordance with Article 71a-d HIO (Health Insurance Ordinance/KVV), cooperation with health insurers
Planned changes to ordinances

Basic knowledge of the Swissmedic approval procedure and the importance of the Pharmaceutical economics and HTA in Switzerland round off the program.

Employees from both domestic and international backgrounds seeking specific knowledge of Market Access in Switzerland
HUB employees responsible for the Swiss Market
Market Access and Medical Affairs Associates
Marketing & Commercial Associates
Anyone who is interested in Market Access